echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Potential "first-in-class" therapy for treating atopic dermatitis obtained clinical proof of concept

    Potential "first-in-class" therapy for treating atopic dermatitis obtained clinical proof of concept

    • Last Update: 2021-10-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On September 27, 2021, ASLAN Pharmaceuticals announced that the monoclonal antibody ASLAN004, which targets the IL-13 receptor α1 subunit (IL-13α1), is used in the treatment of moderate to severe atopic dermatitis (AD).


    Atopic dermatitis is one of the most common skin diseases, with more than 200 million patients worldwide


    ▲ Mechanism of action of ASLAN004 (picture source: ASLANKO official website)

    The results announced today showed that in addition to the primary endpoint, other key efficacy endpoints of the trial also showed significant improvement (p<0.


    in particular:

    In the revised intention-to-treat population (n=29), at the 8th week of treatment, patients in the ASLAN004 group had an average reduction in EASI of 65% from baseline (n=16), compared with 27% of patients in the placebo group (n=13) ( p=0.


    69% of patients in the ASLAN004 group reached EASI-75, and 15% in the placebo group (p=0.


    44% of patients in the ASLAN004 group achieved a score of 0 or 1 in the Investigator's Overall Assessment (IGA), compared with 15% in the placebo group (p=0.


    In all 32 patients who completed at least 29 days of dosing, the EASI of ASLAN004 group was reduced by an average of 73% from baseline at week 8 (n=19), compared with 44% (n=13) in the placebo group (p= 0.


    The specific results of the test are shown in the following table:

    Picture source: reference [1]

    Reference materials:

    [1] ASLAN Pharmaceuticals Announces Positive Data Conclusively Establishing Proof of Concept for ASLAN004 in Atopic Dermatitis.


    (The original text has been deleted)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.